Want to see CLBT full AI Analyst Report?
Top Page
Cellebrite DI
(NASDAQ:CLBT)
Select Model
Select Model
Rating:67Neutral
Price Target:
$11.50
▼(-19.13% Downside)
Action:Downgraded
Date:08/18/26
The score is led by strong financial quality (high margins, robust free cash flow, and a low-leverage balance sheet). Offsetting this are very weak technicals (price far below key moving averages with negative momentum) and a rich valuation (P/E ~44) that leaves less room for execution mistakes. The latest earnings call was mixed, with ARR/revenue guidance lowered but profitability guidance raised, tempering near-term growth confidence.
Positive Factors
Subscription-led recurring growth
Strong ARR growth and a subscription-heavy revenue mix improve visibility, retention potential and scalability. Recurring software revenue can support durable expansion as agencies add users, modules and analytical capabilities.
Negative Factors
Lowered growth outlook
The guidance reset indicates that near-term expansion is less predictable than previously expected. Slower deal conversion and lower expansion assumptions may weigh on recurring growth while management rebuilds execution confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Subscription-led recurring growth
Strong ARR growth and a subscription-heavy revenue mix improve visibility, retention potential and scalability. Recurring software revenue can support durable expansion as agencies add users, modules and analytical capabilities.
Read all positive factors
Cellebrite DI Key Performance Indicators (KPIs)
Any
Revenue by Geography
Maps where sales are coming from across regions, indicating dependence on particular markets, exposure to geopolitical or regulatory risk, and where expansion or slowdown might materially affect overall growth.
Maps where sales are coming from across regions, indicating dependence on particular markets, exposure to geopolitical or regulatory risk, and where expansion or slowdown might materially affect overall growth.
Data provided by:
The Fly
The FlyCellebrite DI (CLBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.82B
Dividend YieldN/A
Average Volume (3M)1.82M
Price to Earnings (P/E)46.9
Beta (1Y)0.74
Revenue Growth17.76%
EPS GrowthN/A
CountryUS
Employees1,285
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)0.24
Shares Outstanding249,439,820
10 Day Avg. Volume1,393,342
30 Day Avg. Volume1,818,489
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)9.30
Price to Sales (P/S)9.47
P/FCF Ratio28.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.75Price Target Upside10.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.33
Revenue Forecast (FY)$563.32M
Cellebrite DI Business Overview & Revenue Model
Company Description
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throu...
How the Company Makes Money
Cellebrite makes money primarily by selling access to its digital intelligence software and related services to customers such as public-sector agencies and enterprises. Key revenue streams include: (1) Software subscriptions/licenses: recurring r...
Cellebrite DI Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The call was mixed. The company reported strong underlying metrics (ARR +21%, revenue +16%, high gross margin and improved EBITDA guidance), meaningful new-product traction (Genesis, Guardian, Advanced Unlocks) and healthy cash/FCF. However, execution and timing issues on several large, cloud/AI deals—driven by new procurement and foreign-entity requirements and lower-than-expected ARR uplift from Insights conversions—led management to lower full-year ARR guidance and caution on near-term growth. Management emphasized improved sales rigor, tighter forecasting, and disciplined cost management, suggesting the company is addressing issues while maintaining confidence in long-term opportunity.Positive Updates
ARR Growth
ARR increased 21% year-over-year to $508 million (Q2 2026), reflecting ongoing subscription momentum despite quarterly execution shortfalls.
Negative Updates
Missed ARR Guidance and Execution Shortfall
The company missed the bottom end of its Q2 ARR guidance and acknowledged it 'did not deliver the ARR and revenue performance expected' due to timing slips on several large transactions.
Read all updates
Q2-2026 Updates
Positive
Negative
ARR Growth
ARR increased 21% year-over-year to $508 million (Q2 2026), reflecting ongoing subscription momentum despite quarterly execution shortfalls.
Read all positive updates
Company Guidance
Management lowered full‑year ARR to $550–560M (≈$15M midpoint reduction; ARR growth 14–16%) and trimmed full‑year revenue to $555–561M (growth ~17–18%) while raising adjusted EBITDA to $153–159M (≈28% margin) and reiterating a target ~30% free cash flow margin for 2026; Q3 guidance is ARR $524–528M (net new ARR $16–20M), revenue $145–148M and adjusted EBITDA $42–45M (29–30% margin). For context, Q2 ARR was $508M (+21%), revenue $131M (+16%), subscription revenue $119.5M (91% of revenue), gross profit $112M (86% margin), adjusted EBITDA $31.8M (24% margin), cash/investments $546M and TTM free cash flow $144.2M (28% margin); growth products drove 25% of the $15M sequential ARR increase, Genesis contributed ≈$400k ARR in late June, Insights reached ~65% of the installed base but is now expected to add only mid‑single digits to ARR, Defense & Intelligence ARR grew 25%, regional ARR mix was Americas 53%/EMEA 34%/APAC 13% (growth rates 19%/23%/29%), Corellium is expected to contribute 1–2 points, Guardian/Pathfinder/Genesis the lower end of mid‑single digits, management expects ~3 points of FX headwind and at least a 1‑point improvement in gross revenue retention.Cellebrite DI Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 514.29M | 475.68M | 401.20M | 325.11M | 270.65M | 246.25M |
| Gross Profit | 426.66M | 400.50M | 338.61M | 271.88M | 219.91M | 203.69M |
| EBITDA | 113.64M | 103.07M | -265.35M | -65.41M | 130.10M | 89.47M |
| Net Income | 58.76M | 78.33M | -283.01M | -81.10M | 120.81M | 71.40M |
Balance Sheet | ||||||
| Total Assets | 994.31M | 938.85M | 690.57M | 532.88M | 403.29M | 339.78M |
| Cash, Cash Equivalents and Short-Term Investments | 442.53M | 437.05M | 447.22M | 302.92M | 183.62M | 181.56M |
| Total Debt | 23.23M | 22.67M | 10.97M | 14.13M | 15.36M | 0.00 |
| Total Liabilities | 456.21M | 454.53M | 354.55M | 498.67M | 329.43M | 413.13M |
| Stockholders Equity | 538.10M | 484.32M | 336.02M | 34.21M | 73.86M | -73.35M |
Cash Flow | ||||||
| Free Cash Flow | 139.59M | 155.73M | 121.56M | 94.14M | 11.49M | 27.94M |
| Operating Cash Flow | 152.97M | 168.96M | 132.17M | 102.06M | 20.58M | 36.05M |
| Investing Cash Flow | -209.64M | -268.25M | -149.47M | -22.54M | -91.23M | 45.23M |
| Financing Cash Flow | 19.31M | 29.64M | 20.65M | 21.77M | 13.97M | -68.40M |
Cellebrite DI Technical Analysis
Negative
14.22
Price Trends
14.21
Negative
13.74
Negative
14.94
Negative
Market Momentum
-1.04
Positive
32.27
Neutral
23.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Negative. The current price of 14.22 is above the 20-day moving average (MA) of 13.80, above the 50-day MA of 14.21, and below the 200-day MA of 14.94, indicating a bearish trend. The MACD of -1.04 indicates Positive momentum. The RSI at 32.27 is Neutral, neither overbought nor oversold. The STOCH value of 23.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLBT.
Cellebrite DI Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.05B | 17.54 | 6.22% | 6.94% | 5.43% | 208.11% | |
71 Outperform | $1.78B | 19.41 | 15.04% | 0.67% | 12.36% | -28.24% | |
67 Neutral | $2.82B | 46.94 | 11.87% | ― | 17.76% | ― | |
67 Neutral | $4.69B | -33.80 | -26.91% | ― | 15.86% | -33.39% | |
65 Neutral | $1.14B | 70.90 | 5.05% | ― | 9.98% | 18.53% | |
63 Neutral | $3.76B | 549.20 | 2.41% | ― | 9.93% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
* Technology Sector Average
CLBT
Cellebrite DI
11.05
-4.78
-30.20%
RDWR
Radware
27.85
3.14
12.71%
EVTC
Evertec
29.89
-6.14
-17.03%
VRNS
Varonis Systems
41.23
-16.73
-28.86%
TENB
Tenable Holdings
34.38
4.37
14.56%
TUYA
Tuya
1.80
-0.64
-26.29%
Cellebrite DI Corporate Events
Cellebrite Announces CEO Transition to Shiven Ramji in Planned Succession
Aug 13, 2026
Effective August 13, 2026, Cellebrite DI Ltd. executed a planned leadership succession in which Thomas E. Hogan stepped down as chief executive officer and resigned from the board of directors by mutual agreement. The company appointed Shiven Ramj...
Cellebrite DI Files Stronger First-Half 2026 Results With Rising Subscription Revenue
Aug 13, 2026
Cellebrite DI Ltd., a digital intelligence solutions provider for law enforcement and government customers, reported interim consolidated financial statements for the six months ended June 30, 2026, filed with the U.S. Securities and Exchange Comm...
Cellebrite Names New CEO as Q2 2026 Growth Slows and Outlook Is Reset
Aug 13, 2026
On August 13, 2026, Cellebrite announced a planned leadership transition in which Shiven Ramji, previously president of products and technology, was appointed chief executive officer and joined the board, succeeding Thomas E. Hogan. The move under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.